Showing results (61-70 of 238) with videos related to
Sort By:
Pageof 24
Proceedings of the National Academy of Sciences of the United States of America|March 2, 2016
Pten loss promotes MAPK pathway dependency in HER2/neu breast carcinomasSaya H Ebbesen, Maurizio Scaltriti, Carl U Bialucha, et al.The Lancet. Oncology|May 21, 2017
Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trialVéronique Diéras, David Miles, Sunil Verma, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2006
p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancerRosana Sáez, Miguel A Molina, Elizabeth E Ramsey, et al.Cancer Research|November 18, 2008
Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235Pieter J A Eichhorn, Magüi Gili, Maurizio Scaltriti, et al.Molecular Oncology|October 1, 2013
Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancerFilippo Montemurro, Aleix Prat, Valentina Rossi, et al.Journal of the National Cancer Institute|April 19, 2007
Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancerMaurizio Scaltriti, Federico Rojo, Alberto Ocaña, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2005
Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancerJosé Baselga, Joan Albanell, Amparo Ruiz, et al.The Journal of Biological Chemistry|July 11, 2009
HER2 carboxyl-terminal fragments regulate cell migration and cortactin phosphorylationJesús García-Castillo, Kim Pedersen, Pier-Davide Angelini, et al.JAMA Oncology|August 18, 2016
Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical TrialSarat Chandarlapaty, David Chen, Wei He, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 2004
Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptorUdo Vanhoefer, Mitra Tewes, Federico Rojo, et al.Pageof 24